TuesdayJun 14, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Moving to Fill Gaps in Treatment and Management of Concussion Among Military Service Members

Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concussion” Although concussion greatly impacts the military, there are significant gaps in the understanding of the optimal diagnostic, treatment, and management criteria Odyssey is looking to bridge this informational gap with its clinical trial and intends to start its U.S. Phase II trials at military training sites, subject to the FDA’s approval of the results of its Phase I study The Center…

Continue Reading

TuesdayJun 14, 2022 9:00 am

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisions Aditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus.  Though the COVID-19 pandemic…

Continue Reading

MondayJun 13, 2022 1:40 pm

WHO Wants Climate Change Efforts to Prioritize Mental Health

Runaway climate change isn’t only about ravaging the planet and making it unlivable for humans, it is also actively about impacting mental health around the world. According to a new policy brief from the World Health Organization (WHO), climate change presents a significant risk to mental health and well-being. The organization has exacerbated economic and environmental risk factors that are associated with a decline in mental health and psychological well-being, especially in countries that aren’t well-equipped to handle mental-health challenges. Launched at the Stockholm+50 conference on June 3, 2022, the policy brief describes the correlation between climate change and mental…

Continue Reading

FridayJun 10, 2022 11:53 am

Experts Urge Cancer Patients Not to Ignore Any Weight, Muscle Loss While on Treatment

A recently conducted survey has demonstrated that most patients with cancer don’t clearly understand the importance of nutritional care during their treatment. The survey, which was authorized by the Irish Society for Clinical Nutrition and Metabolism, discovered a lack of knowledge and even considerable levels of misunderstanding about cancer care and nutrition. The survey included 1,000 respondents, 60% of whom didn’t know that losing muscle or weight during cancer treatment carried risk, including for those who were obese or overweight. It also found that one-half of the respondents didn’t fully comprehend whether nutrition made a difference during cancer care. The…

Continue Reading

FridayJun 10, 2022 9:00 am

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerability While immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemic…

Continue Reading

ThursdayJun 09, 2022 3:18 pm

Study Says Some Allergies Lower Covid Infection Risk

New research has found that individuals with some food allergies may have a reduced risk of contracting the coronavirus. The Human Epidemiology and Response to SARS-CoV-2 (HEROS) study was sponsored and funded by the National Institutes of Health. Its findings were published in the “Journal of Allergy and Clinical Immunology.” The objective of the study was to determine if allergic illnesses such as asthma were linked to household transmission of the SARS-CoV-2 infection. For their research, the scientists following coronavirus infections in more than 4,000 individuals in about 1,400 households in which at least one individual aged 21 or below…

Continue Reading

WednesdayJun 08, 2022 12:32 pm

Study Finds That Brain Tumors May Originate from Different Site

Glioblastoma is one of the most lethal and common primary brain tumors in adults, with a median survival period of about 15 months post diagnosis. New research has found that glioblastoma may originate from stem cells that aren’t in the same region as the tumors it causes. Unlike most types of cancer, glioblastoma is almost always discovered as aggressive and high-grade lesions that are almost impossible to treat using the current treatment methods like chemotherapy, radiation and surgery. Professor Yuan Zhu, the lead author of the study, stated that when a patient presented with neurological symptoms such as vomiting, nausea…

Continue Reading

WednesdayJun 08, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Marks New Milestone in Pursuit of Concussion Treatment with Positive Safety Findings from Cohort I of Phase 1 Clinical Trial for PRV-002

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs The subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has no FDA-approved drug Data from Cohort I of the Phase I study showed that PRV-002 is well-tolerated, with no adverse events being observed The company believes that, if PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, the intranasal brain-targeting will be the key to its success Phase 1 and 2 drugs represent…

Continue Reading

TuesdayJun 07, 2022 11:48 am

At least 4 in 10 Long-COVID Patients Report Symptoms Akin to Fibromyalgia

Tonix Pharmaceuticals recently released data showing that more than 40% of patients living with long COVID usually experience multisite pain much like fibromyalgia. Long COVID occurs when individuals who have been infected with the SARS-CoV-2 virus, which is known to cause the coronavirus, experience long-term effects from their infection. The data was compiled from a retrospective database study that involved more than 50,000 patients who were experiencing symptoms of long COVID. The study found that a high number of participants used opioids to help manage the pain. In the release, Tonix Pharmaceuticals CEO Seth Lederman stated that the analysis was…

Continue Reading

MondayJun 06, 2022 2:28 pm

Study Finds Suicidal Thoughts May Persist after Depression Remission

A new study has found that more than 30% of individuals in remission from major depressive disorder usually continue experiencing suicidal symptoms, even after the most severe stage of the illness has passed. Major depressive disorder accounts for between 60% and 86% of all suicides. The disorder waxes and wanes, with roughly 80% of patients with the disease experiencing no less than five recurrences. Symptoms of suicide may sometimes re-appear, but they don’t always result in action. Despite the close relation between suicidal behavior and thoughts and the disorder, not many studies have looked into suicidal symptoms in connection with…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050